Randomized clinical trial of metronidazole plus erythromycin to prevent spontaneous preterm delivery in fetal fibronectin-positive women

William W. Andrews, Baha M. Sibai, Elizabeth A. Thom, Donald Dudley, J. M. Ernest, Donald McNellis, Kenneth J. Leveno, Ronald Wapner, Atef Moawad, Mary J. O'Sullivan, Steve N. Caritis, Jay D. Iams, Oded Langer, Menachem Miodovnik, Mitchell Dombrowski

Research output: Contribution to journalArticle

100 Scopus citations

Abstract

OBJECTIVE: To estimate whether antibiotic treatment of asymptomatic women with a positive cervical or vaginal fetal fibronectin test in the second trimester would reduce the risk of spontaneous preterm delivery. METHODS: Women were screened between 21 weeks 0 days and 25 weeks 6 days of gestation with cervical or vaginal swabs for fetal fibronectin. Women with a positive test (50 ng/mL or more) were randomized to receive metronidazole (250 mg orally three times per day) and erythromycin (250 mg orally four times per day) or identical placebo pills for 10 days. The primary outcome was spontaneous delivery before 37 weeks' gestation after preterm labor or premature membrane rupture. RESULTS: A total of 16,317 women were screened for fetal fibronectin, and 6.6% had a positive test; 715 fetal fibronectin test-positive women consented to randomization. Outcome data were available for 703 women: 347 in the antibiotic group and 356 in the placebo group. The antibiotic and placebo groups were not significantly different for maternal age (P = .051), ethnicity (P = .849), marital status (P = .127), education (P = .244), and bacterial vaginosis (P = .236). No difference was observed in spontaneous preterm birth before 37 weeks' (odds ratio [OR] 1.17, 95% confidence interval [CI] 0.80, 1.70), less than 35 weeks' (OR 0.92, 95% CI 0.54, 1.56), or less than 32 weeks' (OR 1.94, 95% CI 0.83, 4.52) gestation in antibiotic- compared with placebo-treated women. Among women with a prior spontaneous preterm delivery, the rate of repeat spontaneous preterm delivery at less than 37 weeks' gestation was significantly higher in the active drug compared with the placebo group (46.7% versus 23.9%, P = .039). CONCLUSION: Treatment with metronidazole plus erythromycin of asymptomatic women with a positive cervical or vaginal fetal fibronectin test in the late second trimester does not decrease the incidence of spontaneous preterm delivery.

Original languageEnglish (US)
Pages (from-to)847-855
Number of pages9
JournalObstetrics and gynecology
Volume101
Issue number5
StatePublished - May 2003

    Fingerprint

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Andrews, W. W., Sibai, B. M., Thom, E. A., Dudley, D., Ernest, J. M., McNellis, D., Leveno, K. J., Wapner, R., Moawad, A., O'Sullivan, M. J., Caritis, S. N., Iams, J. D., Langer, O., Miodovnik, M., & Dombrowski, M. (2003). Randomized clinical trial of metronidazole plus erythromycin to prevent spontaneous preterm delivery in fetal fibronectin-positive women. Obstetrics and gynecology, 101(5), 847-855.